{"id":"laropiprant","rwe":[{"pmid":"35460688","year":"2023","title":"A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.","finding":"","journal":"Current problems in cardiology","studyType":"Clinical Study"},{"pmid":"35132998","year":"2022","title":"Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation.","finding":"","journal":"Clinical science (London, England : 1979)","studyType":"Clinical Study"},{"pmid":"32702748","year":"2020","title":"Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.","finding":"","journal":"European heart journal","studyType":"Clinical Study"},{"pmid":"32294459","year":"2020","title":"Industrial Approach to Determine the Relative Contribution of Seven Major UGT Isoforms to Hepatic Glucuronidation.","finding":"","journal":"Journal of pharmaceutical sciences","studyType":"Clinical Study"},{"pmid":"31447131","year":"2019","title":"Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.","finding":"","journal":"Clinical therapeutics","studyType":"Clinical Study"}],"tags":[{"label":"laropiprant","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Prostaglandin D2 receptor","category":"target"},{"label":"PTGDR","category":"gene"},{"label":"TBXA2R","category":"gene"},{"label":"PTGER2","category":"gene"},{"label":"Active","category":"status"},{"label":"Dyslipidemia","category":"indication"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LAROPIPRANT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:50:37.291097+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:01:46.355979+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:50:42.827105+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LAROPIPRANT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:50:43.046465+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Prostanoid DP receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:50:44.075308+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL426559/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:50:43.741138+00:00"}},"allNames":["laropiprant","MK 0524","MK-0524"],"offLabel":[],"synonyms":["laropiprant","MK 0524","MK-0524"],"timeline":[],"aiSummary":"Laropiprant is a marketed drug primarily indicated for dyslipidemia, with a key composition patent expiring in 2028. Its mechanism of action, blocking prostaglandin D2, differentiates it from competitors targeting similar pathways. The primary risk is the competitive landscape, including off-patent drugs like alprostadil and dinoprostone, as well as patent-protected options such as epoprostenol, iloprost, and selexipag.","approvals":[],"ecosystem":[{"indication":"Dyslipidemia","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Prostaglandin D2 receptor","targets":[{"gene":"PTGDR","source":"DrugCentral","target":"Prostaglandin D2 receptor","protein":"Prostaglandin D2 receptor"},{"gene":"TBXA2R","source":"DrugCentral","target":"Thromboxane A2 receptor","protein":"Thromboxane A2 receptor"},{"gene":"PTGER2","source":"DrugCentral","target":"Prostaglandin E2 receptor EP2 subtype","protein":"Prostaglandin E2 receptor EP2 subtype"},{"gene":"PTGDR2","source":"DrugCentral","target":"Prostaglandin D2 receptor 2","protein":"Prostaglandin D2 receptor 2"},{"gene":"PTGER3","source":"DrugCentral","target":"Prostaglandin E2 receptor EP3 subtype","protein":"Prostaglandin E2 receptor EP3 subtype"},{"gene":"PTGER1","source":"DrugCentral","target":"Prostaglandin E2 receptor EP1 subtype","protein":"Prostaglandin E2 receptor EP1 subtype"},{"gene":"PTGIR","source":"DrugCentral","target":"Prostacyclin receptor","protein":"Prostacyclin receptor"},{"gene":"PTGFR","source":"DrugCentral","target":"Prostaglandin F2-alpha receptor","protein":"Prostaglandin F2-alpha receptor"}],"modality":"Small Molecule","drugClass":"laropiprant","explanation":"","oneSentence":"","technicalDetail":"Laropiprant acts as a selective antagonist of the prostaglandin D2 receptor (DP1), inhibiting the vasodilatory effects of prostaglandin D2 and thereby reducing the breakdown of high-density lipoprotein (HDL) and increasing the levels of HDL in the blood."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4326","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LAROPIPRANT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LAROPIPRANT","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:15:54.924206","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:50:45.273189+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"alprostadil","drugSlug":"alprostadil","fdaApproval":"1981-10-16","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"dinoprostone","drugSlug":"dinoprostone","fdaApproval":"1977-08-23","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"epoprostenol","drugSlug":"epoprostenol","fdaApproval":"1995-09-20","patentExpiry":"Mar 15, 2027","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"iloprost","drugSlug":"iloprost","fdaApproval":"2004-12-29","patentExpiry":"Jul 18, 2044","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"selexipag","drugSlug":"selexipag","fdaApproval":"2015-12-21","patentExpiry":"Oct 31, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"treprostinil","drugSlug":"treprostinil","fdaApproval":"2002-05-21","patentExpiry":"Sep 5, 2028","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"laropiprant","indications":{"approved":[{"name":"Dyslipidemia","source":"DrugCentral","snomedId":370992007,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alprostadil","brandName":"alprostadil","genericName":"alprostadil","approvalYear":"1981","relationship":"same-target"},{"drugId":"dinoprostone","brandName":"dinoprostone","genericName":"dinoprostone","approvalYear":"1977","relationship":"same-target"},{"drugId":"epoprostenol","brandName":"epoprostenol","genericName":"epoprostenol","approvalYear":"1995","relationship":"same-target"},{"drugId":"iloprost","brandName":"iloprost","genericName":"iloprost","approvalYear":"2004","relationship":"same-target"},{"drugId":"selexipag","brandName":"selexipag","genericName":"selexipag","approvalYear":"2015","relationship":"same-target"},{"drugId":"treprostinil","brandName":"treprostinil","genericName":"treprostinil","approvalYear":"2002","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT01274559","phase":"PHASE3","title":"Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-01","conditions":["Primary Hypercholesterolemia","Mixed Dyslipidemia"],"enrollment":1173,"completionDate":"2013-02-26"},{"nctId":"NCT01308203","phase":"PHASE4","title":"Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease","status":"TERMINATED","sponsor":"Daniel A. Siniawski","startDate":"2011-10","conditions":["Coronary Artery Disease","Dyslipidemias"],"enrollment":32,"completionDate":"2013-01"},{"nctId":"NCT01054508","phase":"PHASE4","title":"Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2010-06","conditions":["Hypercholesterolemia"],"enrollment":38,"completionDate":"2012-01"},{"nctId":"NCT00769132","phase":"PHASE1","title":"A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08-03","conditions":["Hypercholesterolemia"],"enrollment":26,"completionDate":"2007-11-06"},{"nctId":"NCT01683656","phase":"PHASE4","title":"ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART","status":"TERMINATED","sponsor":"Calmy Alexandra","startDate":"2012-08","conditions":["HIV","Atherosclerosis"],"enrollment":4,"completionDate":"2014-07"},{"nctId":"NCT01118598","phase":"PHASE4","title":"Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2010-06","conditions":["Polycystic Ovary Syndrome"],"enrollment":34,"completionDate":"2012-05"},{"nctId":"NCT00479882","phase":"PHASE3","title":"MK-0524B Lipid Study (MK-0524B-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-15","conditions":["Primary Hypercholesterolemia","Mixed Dyslipidemia"],"enrollment":2414,"completionDate":"2008-06-16"},{"nctId":"NCT01335997","phase":"PHASE3","title":"Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-01","conditions":["Primary Hypercholesterolemia","Mixed Dyslipidemia"],"enrollment":1139,"completionDate":"2012-01-01"},{"nctId":"NCT00289900","phase":"PHASE3","title":"Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01-24","conditions":["Mixed Hyperlipidemia"],"enrollment":2340,"completionDate":"2010-08-06"},{"nctId":"NCT01294683","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02-04","conditions":["Primary Hypercholesterolemia","Dyslipidemia"],"enrollment":977,"completionDate":"2012-01-17"},{"nctId":"NCT00533312","phase":"PHASE2","title":"MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":["Hypercholesterolemia"],"enrollment":407,"completionDate":"2007-01"},{"nctId":"NCT00269217","phase":"PHASE3","title":"Lipid Efficacy Study (0524B-022)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01","conditions":["Primary Hypercholesterolemia","Mixed Hyperlipidemia"],"enrollment":1400,"completionDate":"2007-01"},{"nctId":"NCT00111891","phase":"PHASE2","title":"An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06","conditions":["Dyslipidemia"],"enrollment":575,"completionDate":"2005-08"},{"nctId":"NCT00376584","phase":"PHASE3","title":"Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":["Hypercholesteremia","Hyperlipidemia"],"enrollment":825,"completionDate":"2007-01"},{"nctId":"NCT00378833","phase":"PHASE3","title":"Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":["Hypercholesterolemia","Hyperlipidemia"],"enrollment":1300,"completionDate":"2007-03"},{"nctId":"NCT01052311","phase":"PHASE4","title":"The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2010-07","conditions":["Coronary Artery Disease","Dyslipidemia"],"enrollment":8,"completionDate":"2013-01"},{"nctId":"NCT00533208","phase":"PHASE2","title":"MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-07","conditions":["Seasonal Allergies"],"enrollment":766,"completionDate":"2003-10"},{"nctId":"NCT01583647","phase":"PHASE1","title":"A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06","conditions":["Hypercholesterolemia, Familial","Heterozygous Familial Hypercholesterolemia"],"enrollment":10,"completionDate":"2012-12"},{"nctId":"NCT01012219","phase":"PHASE1","title":"A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":["Primary Hypercholesterolemia","Mixed Hyperlipidemia"],"enrollment":36,"completionDate":"2010-04"},{"nctId":"NCT00783601","phase":"PHASE2","title":"MK0524 Asthma POC Study (0524-008)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-10","conditions":["Asthma"],"enrollment":130,"completionDate":"2005-05"},{"nctId":"NCT00485758","phase":"PHASE3","title":"Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":["Diabetes Mellitus Type 2"],"enrollment":796,"completionDate":"2008-08"},{"nctId":"NCT00384293","phase":"PHASE3","title":"Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":["Hypercholesterolemia, Familial"],"enrollment":937,"completionDate":"2008-08"},{"nctId":"NCT00618995","phase":"PHASE1","title":"A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08","conditions":["Type 2 Diabetes Mellitus"],"enrollment":26,"completionDate":"2007-12"},{"nctId":"NCT00536510","phase":"PHASE3","title":"Effect of MK0524A on Cholesterol Levels (0524A-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":["Hypercholesterolemia","Hyperlipidemia"],"enrollment":646,"completionDate":"2008-03"},{"nctId":"NCT00536237","phase":"PHASE2","title":"MK0524A Phase IIb Study (0524A-011)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-08","conditions":["Flushing"],"enrollment":154,"completionDate":"2006-12"},{"nctId":"NCT00269204","phase":"PHASE3","title":"Lipid Efficacy/Tolerability Study (0524A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12","conditions":["Primary Hypercholesterolaemia","Mixed Hyperlipidaemia"],"enrollment":1620,"completionDate":"2006-12"},{"nctId":"NCT00943124","phase":"PHASE1","title":"MK0524B Bioequivalence Study (0524B-070)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":["Dyslipidemia"],"enrollment":220,"completionDate":"2007-08"},{"nctId":"NCT00944645","phase":"PHASE1","title":"MK0524A Bioequivalence Study (0524A-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10","conditions":["Dyslipidemia"],"enrollment":188,"completionDate":"2007-01"},{"nctId":"NCT01414166","phase":"PHASE3","title":"Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09","conditions":["Dyslipidemia"],"enrollment":244,"completionDate":"2013-02"},{"nctId":"NCT01228019","phase":"","title":"Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-12","conditions":["Hypercholesterolemia","Mixed Dyslipidemia"],"enrollment":1166,"completionDate":"2013-05"},{"nctId":"NCT00664287","phase":"PHASE3","title":"Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":["Dyslipidemia"],"enrollment":0,"completionDate":""},{"nctId":"NCT01451619","phase":"PHASE1","title":"A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11","conditions":["Rosacea"],"enrollment":60,"completionDate":"2012-04"},{"nctId":"NCT00479388","phase":"PHASE3","title":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":["Primary Hypercholesterolemia","Mixed Dyslipidemia"],"enrollment":1216,"completionDate":"2008-10"},{"nctId":"NCT00961636","phase":"PHASE3","title":"A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10","conditions":["Dyslipidemia"],"enrollment":1152,"completionDate":"2011-01"},{"nctId":"NCT02153879","phase":"PHASE4","title":"Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment","status":"COMPLETED","sponsor":"Institut Investigacio Sanitaria Pere Virgili","startDate":"2009-02","conditions":["Type 2 Diabetes Mellitus","Dyslipidemia"],"enrollment":30,"completionDate":"2013-12"},{"nctId":"NCT01239992","phase":"PHASE4","title":"Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia","status":"TERMINATED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2011-06","conditions":["Hyperlipoproteinemia","Metabolic Syndrome"],"enrollment":12,"completionDate":"2013-07"},{"nctId":"NCT00461630","phase":"PHASE3","title":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-01","conditions":["Cardiovascular Disease","Peripheral Arterial Disease","Diabetes Mellitus","Coronary Heart Disease"],"enrollment":25673,"completionDate":"2012-10"},{"nctId":"NCT01942291","phase":"PHASE4","title":"Short-term Effect of Extended-release Niacin on Endothelial Function.","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2012-03","conditions":["Hypoalphalipoproteinemia"],"enrollment":18,"completionDate":"2013-06"},{"nctId":"NCT01391377","phase":"NA","title":"Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease","status":"TERMINATED","sponsor":"Bayside Health","startDate":"2011-07","conditions":["Peripheral Arterial Disease"],"enrollment":7,"completionDate":"2014-12"},{"nctId":"NCT01450410","phase":"PHASE4","title":"Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL","status":"TERMINATED","sponsor":"Xavier Pinto Sala","startDate":"2012-07","conditions":["Dyslipidemias"],"enrollment":12,"completionDate":"2013-05"},{"nctId":"NCT01321034","phase":"PHASE4","title":"Effect of Niacin in the Lipoprotein (a) Concentration","status":"COMPLETED","sponsor":"Instituto Aragones de Ciencias de la Salud","startDate":"2011-10","conditions":["Hypercholesterolemia"],"enrollment":90,"completionDate":"2012-12"},{"nctId":"NCT01126073","phase":"PHASE4","title":"Niacin/Laropiprant and Endothelial Function","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2010-09","conditions":["Coronary Heart Disease"],"enrollment":60,"completionDate":"2011-10"},{"nctId":"NCT01010516","phase":"PHASE4","title":"Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia","status":"UNKNOWN","sponsor":"University of Ioannina","startDate":"2009-10","conditions":["Dyslipidemia"],"enrollment":120,"completionDate":""},{"nctId":"NCT01071525","phase":"PHASE3","title":"The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2010-04","conditions":["Hypercholesterolemia"],"enrollment":30,"completionDate":"2010-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"013266","UNII":"G7N11T8O78","CHEBI":"CHEBI:135942","INN_ID":"8855","UMLSCUI":"C1956497","chemblId":"CHEMBL426559","ChEMBL_ID":"CHEMBL426559","KEGG_DRUG":"D08940","DRUGBANK_ID":"DB11629","PUBCHEM_CID":"9867642","IUPHAR_LIGAND_ID":"3356","MESH_SUPPLEMENTAL_RECORD_UI":"C518174"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"11.8 hours","clearance":"1.21 mL/min/kg","volumeOfDistribution":"1.0 L/kg"},"publicationCount":133,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[{"date":"2023 Aug","pmid":"35460688","title":"A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.","journal":"Current problems in cardiology"},{"date":"2022 Mar 18","pmid":"35132998","title":"Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation.","journal":"Clinical science (London, England : 1979)"},{"date":"2020 Sep 14","pmid":"32702748","title":"Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.","journal":"European heart journal"},{"date":"2020 Jul","pmid":"32294459","title":"Industrial Approach to Determine the Relative Contribution of Seven Major UGT Isoforms to Hepatic Glucuronidation.","journal":"Journal of pharmaceutical sciences"},{"date":"2019 Sep","pmid":"31447131","title":"Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.","journal":"Clinical therapeutics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","brandName":"LAROPIPRANT","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:50:45.273189+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}